Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
Company Announcements
Ipsen’s Odevixibat Study: A Potential Game-Changer for Alagille Syndrome
2d ago
0MH6
Premium
Company Announcements
Ipsen’s Real-World Study on Cabozantinib and Nivolumab: A Potential Game-Changer for RCC Treatment
11d ago
0MH6
Premium
Company Announcements
Ipsen’s Innovative Approach to PBC: A Study on Itch and Sleep Patterns
11d ago
0MH6
Premium
Company Announcements
Ipsen’s New Study on Palovarotene: Implications for Liver-Impaired Patients
11d ago
0MH6
Premium
Company Announcements
Ipsen’s Odevixibat Study: A Closer Look at Pregnancy and Lactation Safety
11d ago
0MH6
Premium
Company Announcements
Ipsen’s Latest Clinical Study on IPN01194: A Potential Game-Changer in Oncology
12d ago
0MH6
Premium
Company Announcements
Ipsen’s Phase II Osteosarcoma Study: A Potential Game Changer?
12d ago
0MH6
Premium
Company Announcements
Ipsen’s Real-World Study on Elafibranor for PBC: A Potential Game-Changer?
12d ago
0MH6
Premium
Company Announcements
Ipsen’s Elafibranor Study: A Potential Breakthrough for PBC Treatment
12d ago
0MH6
Premium
Company Announcements
Ipsen’s Promising Phase II Migraine Study: A Potential Game Changer
12d ago
0MH6
Premium
Company Announcements
Ipsen’s Latest Study on Abobotulinumtoxin A: Implications for Investors
12d ago
0MH6
Premium
Company Announcements
Ipsen’s Promising Study on IPN10200 for Cervical Dystonia: A Potential Game-Changer?
12d ago
0MH6
Premium
Company Announcements
Ipsen’s New Drug Study: A Potential Game-Changer for Advanced Solid Tumors
12d ago
0MH6
Premium
Company Announcements
Ipsen’s Increlex® Study: Long-term Safety and Effectiveness in Focus
13d ago
0MH6
Premium
Company Announcements
Ipsen’s Phase III Study on Elafibranor: A Potential Game-Changer for Liver Disease Treatment
13d ago
0MH6
Premium
Company Announcements
Ipsen’s Dysport® Study: A Potential Game-Changer for Chronic Migraine Prevention
13d ago
0MH6
Premium
Company Announcements
Ipsen’s Study on Post-Stroke Spasticity: A Potential Game Changer for Patient Care
13d ago
0MH6
Premium
Company Announcements
Ipsen’s IPN10200 Study: A Potential Game-Changer in Spasticity Treatment
13d ago
0MH6
Premium
Company Announcements
Ipsen’s Dysport® Trial: A New Hope for Migraine Prevention?
13d ago
0MH6
Premium
Company Announcements
Ipsen’s New Study on IPN10200: A Potential Game-Changer for Cervical Dystonia Treatment
1M ago
Premium
Company Announcements
Ipsen’s Real-World Study on Renal Cell Carcinoma Treatment: Key Update
1M ago
Premium
Company Announcements
Ipsen’s Phase III Elafibranor Study: A Potential Breakthrough in PBC Treatment
1M ago
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.